Literature DB >> 31255688

Status of vitamin D and the associated host factors in pulmonary tuberculosis patients and their household contacts: A cross sectional study.

Sudhasini Panda1, Ambrish Tiwari1, Kalpana Luthra1, S K Sharma2, Archana Singh3.   

Abstract

Innate immunity plays an important role in pathophysiology of tuberculosis which is influenced by various host factors. One such factor is vitamin D which, along with its associated molecule, can alter the host defense against Mycobacterium Tuberculosis (M.Tb.) via altered production of cathelicidin and nitric oxide, both having bactericidal effect. Therefore, assessment of vitamin D and its associated molecules in tuberculosis patients and household contacts as compared to healthy controls were done and the implication of these findings in susceptibility to tuberculosis (TB) was studied. 80 active TB patients, 75 household contacts and 70 healthy controls were included. Vitamin D receptor (VDR), vitamin D binding protein (VDBP) and inducible nitric oxide synthase (iNOS) mRNA levels were studied using quantitative PCR. Serum VDR, cathelicidin, and iNOS levels were measured using ELISA. Vitamin D and NO levels were measured in serum using chemiluminescence based immunoassay and greiss reaction based colorimetry kit respectively. Decreased serum levels of vitamin D were observed in active TB patients as compared to healthy controls (p < 0.001). VDR and iNOS mRNA levels were found to be significantly lower in active TB patients compared to household contacts and healthy controls (p < 0.0001 and 0.005 respectively). VDBP mRNA expression was found to be lower in active TB group as compared to household contacts and healthy controls however the difference was not found to be significant (p > 0.21). Although, mRNA expression of VDR, VDR protein and iNOS along with vitamin D levels were significantly (p < 0.05) higher in household contacts compared to active TB group. However, levels of iNOS, NO and cathelicidin were found to be higher in TB patients as compared to household contacts and healthy controls (p < 0.01, 0.05 and 0.01 respectively). Higher levels of Vitamin D along with VDR and iNOS expression in household contacts as compared to active TB patients suggest vitamin D might have a protective role against TB plausibly decreasing disease susceptibility. Low vitamin D levels in active TB patients warrants further studies to determine the role of vitamin D supplementation in prevention and treatment of TB.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cathelicidin; Nitric oxide; Tuberculosis; VDR; Vitamin D; iNOS

Mesh:

Substances:

Year:  2019        PMID: 31255688     DOI: 10.1016/j.jsbmb.2019.105419

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  4 in total

1.  Lower levels of vitamin D are associated with SARS-CoV-2 infection and mortality in the Indian population: An observational study.

Authors:  Sunali Padhi; Subham Suvankar; Venketesh K Panda; Abhijit Pati; Aditya K Panda
Journal:  Int Immunopharmacol       Date:  2020-09-14       Impact factor: 4.932

2.  Association of vitamin D pathway genes polymorphisms with pulmonary tuberculosis susceptibility in a Chinese population.

Authors:  Tian-Ping Zhang; Shuang-Shuang Chen; Gen-You Zhang; Si-Jiu Shi; Li Wei; Hong-Miao Li
Journal:  Genes Nutr       Date:  2021-04-21       Impact factor: 5.523

3.  Evaluation of circulating serum cathelicidin levels as a potential biomarker to discriminate between active and latent tuberculosis in Uganda.

Authors:  Ester Lilian Acen; David Patrick Kateete; William Worodria; Ronald Olum; Moses L Joloba; Mudarshiru Bbuye; Irene Andia Biraro
Journal:  PLoS One       Date:  2022-08-26       Impact factor: 3.752

Review 4.  rs7041 and rs4588 Polymorphisms in Vitamin D Binding Protein Gene (VDBP) and the Risk of Diseases.

Authors:  Dominika Rozmus; Janusz Płomiński; Klaudia Augustyn; Anna Cieślińska
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.